Clinical Features of Cytotoxic Lesions of the Corpus Callosum Associated with Aneurysmal Subarachnoid Hemorrhage

References

1. 1.↵
   1. Bulakbasi N,
   2. Kocaoglu M,
   3. Tayfun C, et al

   . Transient splenial lesion of the corpus callosum in clinically mild influenza-associated encephalitis/encephalopathy. AJNR Am J Neuroradiol 2006;27:1983–86 pmid:17032879

   Abstract/FREE Full Text
2. 2.
   1. Gallucci M,
   2. Limbucci N,
   3. Paonessa A, et al

   . Reversible focal splenial lesions. Neuroradiology 2007;49:541–44 doi:10.1007/s00234-007-0235-z pmid:17522852

   CrossRefPubMedWeb of Science
3. 3.
   1. Garcia-Monco JC,
   2. Cortina IE,
   3. Ferreira E, et al

   . Cytotoxic lesions of the corpus callosum syndrome (RESLES): what’s in a name? J Neuroimaging 2011;21:e1–14 doi:10.1111/j.1552-6569.2008.00279.x pmid:18681931

   CrossRefPubMedWeb of Science
4. 4.
   1. Gürtler S,
   2. Ebner A,
   3. Tuxhorn I, et al

   . Transient lesion in the splenium of the corpus callosum and antiepileptic drug withdrawal. Neurology 2005;65:1032–36 doi:10.1212/01.wnl.0000179301.96652.27 pmid:16217055

   CrossRefPubMed
5. 5.
   1. Güven H,
   2. Delibaş S,
   3. Comoğlu SS

   . Transient lesion in the splenium of the corpus callosum due to carbamazepine. Turk Neurosurg 2008;18:264–70 pmid:18814116

   PubMed
6. 6.
   1. Kim SS,
   2. Chang KH,
   3. Kim ST, et al

   . Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? AJNR Am J Neuroradiol 1999;20:125–29 pmid:9974067

   Abstract/FREE Full Text
7. 7.
   1. Maeda M,
   2. Tsukahara H,
   3. Terada H, et al

   . Cytotoxic lesions of the corpus callosum with restricted diffusion in a wide spectrum of diseases and conditions. J Neuroradiol 2006;33:229–36 doi:10.1016/S0150-9861(06)77268-6 pmid:17041527

   CrossRefPubMedWeb of Science
8. 8.
   1. Mori H,
   2. Maeda M,
   3. Takanashi J, et al

   . Cytotoxic lesions of the corpus callosum in the corpus callosum following rapid withdrawal of carbamazepine after neurosurgical decompression for trigeminal neuralgia. J Clin Neurosci 2012;19:1182–84 doi:10.1016/j.jocn.2011.09.017 pmid:22349431

   CrossRefPubMed
9. 9.↵
   1. Takanashi J,
   2. Barkovich AJ,
   3. Shiihara T, et al

   . Widening spectrum of a reversible splenial lesion with transiently reduced diffusion. AJNR Am J Neuroradiol 2006;27:836–38 pmid:16611774

   Abstract/FREE Full Text
10. 10.
    1. Takanashi J,
    2. Tada H,
    3. Maeda M, et al

    . Encephalopathy with a reversible splenial lesion is associated with hyponatremia. Brain Dev 2009;31:217–20 doi:10.1016/j.braindev.2008.04.002 pmid:18490123

    CrossRefPubMedWeb of Science
11. 11.
    1. Abe E,
    2. Kajiwara H,
    3. Goda M, et al

    . Clinically mild encephalitis/encephalopathy with a reversible splenial lesion, indistinguishable from multiple cerebral infarction: a case report [in Japanese]. Nosotchu 2014;36:443–48 doi:10.3995/jstroke.36.443

    CrossRef
12. 12.
    1. Tung CS,
    2. Wu SL,
    3. Tsou JC, et al

    . Marchiafava-Bignami disease with widespread lesions and complete recovery. AJNR Am J Neuroradiol 2010;31:1506–07 doi:10.3174/ajnr.A1897 pmid:20019108

    Abstract/FREE Full Text
13. 13.↵
    1. Tada H,
    2. Takanashi J,
    3. Barkovich AJ, et al

    . Clinically mild encephalitis/encephalopathy with a cytotoxic lesions of the corpus callosum. Neurology 2004;63:1854–58 doi:10.1212/01.wnl.0000144274.12174.cb pmid:15557501

    Abstract/FREE Full Text
14. 14.↵
    1. Starkey J,
    2. Kobayashi N,
    3. Numaguchi Y, et al

    . Cytotoxic lesions of the corpus callosum that show restricted diffusion: mechanisms, causes, and manifestations. Radiographics 2017;37:562–76 doi:10.1148/rg.2017160085 pmid:28165876

    CrossRefPubMed
15. 15.↵
    1. Gaur P,
    2. Dixon L,
    3. Jones B, et al

    . COVID-19-associated cytotoxic lesions of the corpus callosum. AJNR Am J Neuroradiol 2020;41:1905–07 doi:10.3174/ajnr.A6713 pmid:32819904

    Abstract/FREE Full Text
16. 16.↵
    1. Yamazaki T,
    2. Sasaki T,
    3. Kubota T, et al

    . Reversible focal splenial lesion of the corpus callosum in aneurysmal subarachnoid hemorrhage [in Japanese]. Progress in CI 2012;34:93–98
17. 17.↵
    1. Rinkel GJ,
    2. van Gijn J,
    3. Wijdicks EF

    . Subarachnoid hemorrhage without detectable aneurysm: a review of the causes. Stroke 1993;24:1403–09 doi:10.1161/01.str.24.9.1403 pmid:8362440

    Abstract/FREE Full Text
18. 18.↵
    1. Vergouwen MD,
    2. Vermeulen M,
    3. van Gijn J, et al

    . Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke 2010;41:2391–95 doi:10.1161/STROKEAHA.110.589275 pmid:20798370

    Abstract/FREE Full Text
19. 19.↵
    1. Aboitiz F,
    2. Scheibel AB,
    3. Fisher RS, et al

    . Fiber composition of the human corpus callosum. Brain Res 1992;598:143–53 doi:10.1016/0006-8993(92)90178-c pmid:1486477

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Uchida K,
    2. Shirakawa M,
    3. Sakamoto D, et al

    . A case of reversible splenial lesion after surgical resection of arteriovenous malformation [in Japanese]. Brain Nerve 2013;65:212–13 pmid:23399678

    PubMed
21. 21.↵
    1. Sorimachi T,
    2. Yajima N,
    3. Sasaki O, et al

    . Hematoma in the splenium of the corpus callosum in the subacute stage of subarachnoid hemorrhage: three case reports. Neurol Med Chir (Tokyo) 2010;50:209–12 doi:10.2176/nmc.50.209 pmid:20339269

    CrossRefPubMed
22. 22.↵
    1. Hadeishi H,
    2. Suzuki A,
    3. Yasui N, et al

    . Diffusion-weighted magnetic resonance imaging in patients with subarachnoid hemorrhage. Neurosurgery 2002;50:741–47 doi:10.1097/00006123-200204000-00010 pmid:11904024

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Graetz D,
    2. Nagel A,
    3. Schlenk F, et al

    . High ICP as trigger of proinflammatory IL-6 cytokine activation in aneurysmal subarachnoid hemorrhage. Neurol Res 2010;32:728–35 doi:10.1179/016164109X12464612122650 pmid:19682408

    CrossRefPubMed
24. 24.↵
    1. Fujita K,
    2. Kusunoki T,
    3. Noda M, et al

    . Normal pressure hydrocephalus (NPH) following subarachnoid hemorrhage (SAH)-clinical consideration of CT and development of hydrocephalus after SAH [in Japanese]. No To Shinkei 1981;33:845–51 pmid:7284211

    PubMed
25. 25.↵
    1. Liu WM,
    2. Lin CH

    . A reversible stroke-like splenial lesion in viral encephalopathy. Acta Neurol Taiwan 2013;22:117–21 pmid:24030090

    PubMed
26. 26.↵
    1. Moritani T,
    2. Ekholm S,
    3. Westesson PL

    . Diffusion-Weighted MR Imaging of the Brain. 2nd ed. Springer-Verlag; 2009:37–38
27. 27.↵
    1. Gaetani P,
    2. Tartara F,
    3. Pignatti P, et al

    . Cisternal CSF levels of cytokines after subarachnoid hemorrhage. Neurol Res 1998;20:337–42 doi:10.1080/01616412.1998.11740528 pmid:9618698

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Mathiesen T,
    2. Edner G,
    3. Ulfarsson E, et al

    . Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-alpha following subarachnoid hemorrhage. J Neurosurg 1997;87:215–20 doi:10.3171/jns.1997.87.2.0215 pmid:9254084

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Kahilogullari G,
    2. Comert A,
    3. Ozdemir M, et al

    . Arterial vascularization patterns of the splenium: an anatomical study. Clin Anat 2013;26:675–81 doi:10.1002/ca.22114 pmid:23564403

    CrossRefPubMed
30. 30.↵
    1. Kakou M,
    2. Velut S,
    3. Destrieux C

    . Arterial and venous vascularization of the corpus callosum [in French]. Neurochirurgie 1998;44(1 Suppl):31–37

    PubMed
31. 31.↵
    1. Tetsuka S

    . Reversible lesion in the splenium of the corpus callosum. Brain Behav 2019;9:e0144 doi:10.1002/brb3.1440 pmid:31588684

    CrossRefPubMed
32. 32.↵
    1. Satoh S,
    2. Suzuki Y,
    3. Ikegaki I, et al

    . The effects of HA1077 on the cerebral circulation after subarachnoid haemorrhage in dogs. Acta Neurochir (Wien) 1991;110:185–88 doi:10.1007/BF01400689 pmid:1927613

    CrossRefPubMed